|

Olaparib; 177Lu-DOTATATE Clinical Trials

1 actively recruiting trial

No change since May 2026

Pipeline

Phase 1/2: 1

Top Sponsors

  • Fundación de investigación HM1

Indications

  • Solid Tumor Refractory to Conventional Treatment1
  • Osteosarcoma Recurrent1
  • DIPG1
  • Neuroblastoma Recurrent1
  • Carcinoma Adrenal1

Other1 trial

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.